CCDS-O practice question 11 of 25

review] A female patient presents for her yearly wellness check-up. Her vital signs are within normal limits with the exception of dyspnea. Her…

Full set: 140 questions
review] A female patient presents for her yearly wellness check-up. Her vital signs are within normal limits with the exception of dyspnea. Her weight is 165 lbs, up 10 lbs from her previous clinic visit 2 weeks prior. Problem list includes diagnoses of obesity, COPD, heart failure, and diabetes without complications. The patient’s A1c noted 9.2 up from 7.2 from previous year wellness exam. Based on the clinical indicators, which of the following medications should be evaluated and addressed during this clinic visit?
Answer options
A: Megace and ferrous sulfate
B: Metformin and methotrexate
C: NovoLog and Lasix Correct answer
D: Wellbutrin and Allegra
Correct Answer:
C. NovoLog and Lasix
Explanation

The patient's clinical presentation includes significant indicators for both heart failure exacerbation and poorly controlled diabetes. The 10-pound weight gain in two weeks and dyspnea are classic signs of fluid retention due to heart failure, warranting an evaluation of diuretic therapy like Lasix. The A1c of 9.2 is well above the target for controlled diabetes, indicating a need to review and potentially adjust the patient's antidiabetic regimen, which could include insulin like NovoLog. Addressing these two issues is the clinical priority based on the provided data.

Why Incorrect

A. Megace is an appetite stimulant, which is contraindicated given the patient's obesity and recent weight gain. Ferrous sulfate is for anemia, which is not indicated.
B. Methotrexate is an immunosuppressant used for autoimmune diseases or cancer and is not relevant to the patient's presented problems.
D. Wellbutrin (antidepressant) and Allegra (antihistamine) do not address the acute clinical indicators of heart failure exacerbation or uncontrolled diabetes.

References

1. American Diabetes Association. (2022). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care, 45(Supplement1), S125–S143. https://doi.org/10.2337/dc22-S009 (Section 9.5 discusses insulin therapy initiation when A1c is high).

2. Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012 (Section 7.3.2 discusses the use of diuretics for congestion management).

Scroll to Top